Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable *vanA* *Enterococcus faecium* ST1421-CT1134 clone, Denmark, 2015 to March 2019

Anette M Hammerum¹, Ulrik S Justesen², Mette Pinholt³, Louise Roer¹, Hülya Kaya¹, Peder Worning³, Sanne Nygaard⁴, Michael Kemp², Marianne Engell Clausen⁵, Karen Leth Nielsen⁶, Jurgita Samulionienė⁷, Mona Kjærsgaard⁸, Claus Østergaard⁹, John Coia¹⁰, Turid Snekløth Søndergaard¹¹, Shahin Gaini^{12,13,14}, Kristian Schønning^{3,15}, Henrik Westh^{3,15}, Henrik Hasman¹, Barbara Juliane Holzknecht⁴

1. Department for Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark
2. Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark
3. Department of Clinical Microbiology, Hvidovre University Hospital, Hvidovre, Denmark
4. Department of Clinical Microbiology, Herlev and Gentofte University Hospital, Herlev, Denmark
5. Department of Clinical Microbiology, Slagelse Hospital, Slagelse, Denmark
6. Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark
7. Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark
8. Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark
9. Department of Clinical Microbiology, Lillebaelt Hospital, Vejle, Denmark
10. Department of Clinical Microbiology, Hospital South West Jutland, Esbjerg, Denmark
11. Department of Clinical Microbiology, Hospital Sønderjylland, Sønderborg, Denmark
12. Medical Department, National Hospital Faroe Islands, Torshavn, Faroe Islands
13. Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
14. Centre of Health Research, University of the Faroe Islands, Torshavn, Faroe Islands
15. Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Correspondence: Anette M Hammerum (ama@ssi.dk)

Citation style for this article:

Hammerum Anette M, Justesen Ulrik S, Pinholt Mette, Roer Louise, Kaya Hülya, Worning Peder, Nygaard Sanne, Kemp Michael, Clausen Marianne Engell, Nielsen Karen Leth, Samulionienė Jurgita, Kjærsgaard Mona, Østergaard Claus, Coia John, Søndergaard Turid Snekløth, Gaini Shahin, Schønning Kristian, Westh Henrik, Hasman Henrik, Holzknecht Barbara Juliane. Surveillance of vancomycin-resistant enterococci reveals shift in dominating clones and national spread of a vancomycin-variable *vanA* *Enterococcus faecium* ST1421-CT1134 clone, Denmark, 2015 to March 2019. *Euro Surveill*. 2019;24(34):pii=1900503. <https://doi.org/10.2807/1560-7917.ES.2019.24.34.1900503>

Article submitted on 06 Aug 2019 / accepted on 21 Aug 2019 / published on 22 Aug 2019

We describe clonal shifts in *vanA* *Enterococcus faecium* isolates from clinical samples obtained from patients in Denmark from 2015 to the first quarter (Q1) of 2019. During Q1 2019, the vancomycin-variable enterococci (VVE) ST1421-CT1134 *vanA* *E. faecium* became the most dominant *vanA* *E. faecium* clone and has spread to all five regions in Denmark. Among 174 *E. faecium* isolates with *vanA*, *vanB* or *vanA/vanB* genes in Q1 2019, 44% belonged to this type.

We describe the clonal shift for *vanA* *Enterococcus faecium* during the last 4 years and the national spread of a vancomycin-variable *vanA* *E. faecium* ST1421-CT1134 clone in Denmark. The aim is to highlight the importance of using molecular methods for detecting vancomycin-variable enterococci (VVE), and to alert other countries about this emerging nosocomial clone.

Vancomycin-variable enterococci

Vancomycin-variable enterococci (VVE) are *E. faecium* harboring the *vanA* gene complex, but being phenotypically vancomycin susceptible [1,2]. VVE can only be detected by molecular methods and cannot be

cultured on selective vancomycin-containing media. Different clones of VVE have caused nosocomial outbreaks and development of vancomycin-resistant revertant mutants *in vitro* and *in vivo* has been described [1,3-5]. This makes the detection of VVE highly important in clinical samples in order to assure relevant antibiotic treatment and in screening samples to avoid nosocomial spread. In 2015 and 2016, sporadic VVE with different genetic background were detected in the Capital Region of Denmark, in connection with vancomycin-resistant enterococci (VRE) outbreaks (data not shown). In 2016, a VVE clone belonging to ST1421-CT1134, which displays variable vancomycin susceptibility (minimum inhibitory concentration (MIC) 1 to ≥ 256 mg/ml) was detected in screening samples from a hospital in the Capital Region [5]. One strain, Efm-V1511, belonging to this clone was characterised by Hansen et al. [5]. Efm-V1511 had a 49.6 Kp plasmid, which carried the Tn1546 (*vanA* transposon). Tn1546 was truncated in *vanX* by a 252 bp 3' deletion explaining the vancomycin susceptibility of Efm-V1511. In ST1421-CT1134 isolates resistant to vancomycin, resistance could be attributed to changes in *ddl* disrupting

FIGURE 1

The five healthcare regions and the 10 Departments of Clinical Microbiology, Denmark, 2019

DCM: Department of Clinical Microbiology; ND: not detected.

Modified from DANMAP 2017 [7].

gene function sometimes accompanied by changes in *vanS*, increased pHVH-V1511 copy number or the existence of an additional *vanA*-containing plasmid encoding a functional *vanX* [5].

National surveillance of vancomycin-resistant and vancomycin-variable enterococci

We have previously described the surveillance of vancomycin-resistant enterococci (VRE) in clinical isolates in Denmark from 2005 to 2015 [6]. In the present study, we follow up and describe the data from isolates obtained from 2016 through the first quarter (Q1) of 2019. Since 2005, VRE isolates from clinical samples, e.g. urine, blood and tissue, as opposed to screening (faecal) isolates have been voluntarily submitted to Statens Serum Institut (SSI) from Danish Departments of Clinical Microbiology (DCM) for species identification, genotyping and surveillance (Figure 1) [7]. Only one isolate per patient per 12 months was included. All VRE isolates (699 *E. faecium* and 30 *E. faecalis*) were tested for the presence of vancomycin resistance genes *vanA* and *vanB* by PCR from 2005 through 2014. From 2015 through Q1 2019, all clinical VRE/VVE isolates ($n=1,935$) underwent whole-genome sequencing (WGS) as previously described [6]. From the WGS data, multilocus sequence type (MLST), and *van* genes were extracted *in silico*. The isolates were further subtyped

in SeqSphere+ (Ridom GmbH, Münster, Germany (<http://www.ridom.de/seqsphere/>)) using the cgMLST scheme by de Been et al. [8] for *E. faecium*.

VVE diagnostic algorithms have differed substantially over time and between the five Danish regions. In 2017, testing of phenotypically vancomycin-susceptible *E. faecium* isolates from blood cultures for the presence of *vanA/vanB* genes by PCR was introduced in the DCMs in the Capital Region. During 2018, this was expanded to testing of all clinical *E. faecium* isolates. During 2018, molecular testing by PCR of *E. faecium* from all clinical samples was also implemented in one of the four DCMs in the Region of Southern Denmark. Furthermore, *E. faecium* isolates from blood cultures were tested by PCR for *vanA/vanB* genes in another DCM in the Region of Southern Denmark and in the DCM in the Central Denmark Region in 2018. In Q1 2019, diagnostic algorithms to detect VVE have expanded. Most of the DCMs across Denmark test at least all blood culture *E. faecium* isolates for the presence of *vanA* genes using PCR.

Enterococcus faecium and *Enterococcus faecalis* isolates from clinical samples carrying *vanA* and *vanB* genes

From 2005 to Q1 2019, 2,503 *vanA E. faecium*, 74 *vanB E. faecium*, 32 *vanA/vanB E. faecium*, 12 *vanA E. faecalis*, and 43 *vanB E. faecalis* from clinical samples were submitted to SSI (Figure 2).

Emergence and disappearance of major *Enterococcus faecium* clones

Of the 1,935 VRE/VVE isolates obtained from 2015 through Q1 2019, 1,910 were *E. faecium* and 25 *E. faecalis* (Figure 2).

The *E. faecium* isolates belonged to 29 sequence types (STs). ST80 (22%), ST203 (65%) and ST1421 (9%) were most prevalent. Typing by cgMLST revealed 156 different complex types (CTs).

The 13 most common types of *vanA*, *vanB* and *vanA/vanB E. faecium* from 2015 to Q1 2019 are shown in Table 1. From 2015 to 2019, three types were dominating: ST80-CT14 *vanA E. faecium*, ST203-CT859 *vanA E. faecium* and ST1421-CT1134 *vanA E. faecium* (Table 1). In 2015, 22% of the *E. faecium* isolates belonged to ST80-CT14 *vanA E. faecium*. The type decreased during 2016.

ST203-CT859 *vanA E. faecium* isolates were first detected during the end of 2014 [6]. It emerged very fast and was the most prevalent *vanA E. faecium* type (together with its subtypes CT1051 and CT1507) during 2015 to 2017, but decreased in 2018 (Table 1). In Q1 2019 only 12% of the VRE/VVE *E. faecium* isolates belonged to ST203-CT859.

In 2017, 3% of the *E. faecium* isolates belonged to the VVE clone, ST1421-CT1134 *vanA E. faecium*. This type

FIGURE 2

Vancomycin-resistant and vancomycin-variable *Enterococcus faecium* and vancomycin-resistant *E. faecalis* isolates from clinical samples carrying van genes, Denmark, 2005–Q1 2019 (n = 2,664)

Q1: first quarter.

was only detected from clinical samples from the Capital Region. In 2018, 34% of the *E. faecium* isolates belonged to ST1421-CT1134 and were detected in the Capital Region, the Region Zealand and from one DCM in the Region of Southern Denmark (Table 1, Table 2). During Q1 2019, ST1421-CT1134 *vanA E. faecium* was the most prevalent type (44%) (Table 1). It was detected in all five regions of Denmark, 50 isolates from the Capital Region, one isolate from Region Zealand, 23 isolates from the Region of Southern Denmark, two isolates from Central Denmark Region and one isolate from the North Denmark Region (Table 2). Furthermore, ST1421-CT1134 *vanA E. faecium* spread to the Faroe Islands during 2018 and 2019 (data not shown).

Discussion and conclusion

During 2005 to Q1 2019, most of the Danish clinical VRE isolates have been *vanA E. faecium* isolates. This study shows that predominating clones shifted over time and, importantly, the emergence of a vancomycin-variable clone, ST1421-CT1134 *vanA E. faecium*, that has spread to all the five Danish regions in 2019.

Although the *E. faecium* isolates belonged to 156 CTs, three types (ST80-CT14 *vanA E. faecium*, ST203-CT859 *vanA E. faecium*, ST1421-CT1134 *vanA E. faecium*) have dominated during the last 4 years.

ST80-CT14 *vanA E. faecium* was highly prevalent in the Capital Region during 2012 to 2015 [9]. The *vanA E. faecium* constituting Group2_ST80 in the paper by Pinholt et al. [9] belonged to ST80-CT14 (data not shown). On a national level, the numbers of ST80-CT14 *vanA E. faecium* decreased during 2016 to 2018, and this clone was not detected during Q1 2019.

ST203-CT859 *vanA E. faecium* emerged during 2015 through 2017 and nearly disappeared 2019. This clone has spread to Sweden, the Faroe Islands and Greenland [6,7].

Because of differences in diagnostic algorithms, there is a detection bias of VVE. It seems very likely that ST1421-CT1134 *vanA E. faecium* have been under-reported in some regions at least during some periods. Thus, the rising incidence could partly be explained by

TABLE 1

Description of the most common types of *vanA* and/or *vanB* *Enterococcus faecium* by MLST and cgMLST, Denmark, 2015–Q1 2019 (n = 1,910)

Types	2015 (n = 369)		2016 (n = 427)		2017 (n = 425)		2018 (n = 515)		Q1 2019 (n = 174)	
	n	%	n	%	n	%	n	%	n	%
ST80-CT14 <i>vanA</i>	81	22	38	9	15	4	1	<1	ND	ND
ST80-CT24 <i>vanA</i>	23	6	19	4	11	3	2	<1	4	2
ST80-CT860 <i>vanA</i>	7	2	11	3	ND	ND	ND	ND	ND	ND
ST80-CT866 <i>vanA</i>	14	4	10	2	7	2	ND	ND	ND	ND
ST80-CT991 <i>vanA</i>	ND	ND	11	3	9	2	6	1	ND	ND
ST80-CT1160 <i>vanA</i>	ND	ND	ND	ND	7	2	10	2	ND	ND
ST80-CT1064 <i>vanA/vanB</i>	ND	ND	2	<1	8	2	23	5	4	2
ST80-CT1729 <i>vanA</i>	ND	ND	ND	ND	ND	ND	22	4	2	1
ST117-CT873 <i>vanA</i>	5	1	12	3	ND	ND	ND	ND	ND	ND
ST117-CT1180 <i>vanA</i>	ND	ND	ND	ND	9	2	30	6	7	4
ST117-CT36 <i>vanB</i>	ND	ND	ND	ND	ND	ND	2	<1	16	9
ST203-CT859 (subtypes CT1051 and CT1507) <i>vanA</i>	188	51	271	64	265	63	161	31	20	12
ST1421-CT1134 <i>vanA</i>	ND	ND	2	<1	13	3	176	34	77	44
Other types	51	14	51	12	81	19	82	16	44	25

CT: cluster type (cgMLST); MLST: multilocus sequence typing; ND: not detected; ST: sequence type (MLST); Q1: first quarter.

TABLE 2

Regional occurrence of ST1421-CT1134 *vanA* *E. faecium*, Denmark, 2016–Q1 2019 (n = 268)

Region	2016 (n = 2)	2017 (n = 13)	2018 (n = 176)	Q1 2019 (n = 77)
Capital Region of Denmark	2	9	158	50
Region Zealand	ND	3	9	1
Region of Southern Denmark	ND	ND	9	23
Central Denmark Region	ND	ND	ND	2
North Denmark Region	ND	1	ND	1

Q1: first quarter.

increasing molecular testing of vancomycin susceptible isolates. However, a sharply increasing incidence has also been seen in DCM with extensive testing for VVE.

The origin of ST80-CT14 *vanA* *E. faecium* and ST203-CT859 *vanA* *E. faecium* are still unknown. *vanA* *E. faecium* isolates belonging to ST1421-CT1134 have also been reported from Australia, but these isolates have not been VVE [10]. Why these three clones were so successful is unknown.

The spread of the VVE clone, ST1421-CT1134 *vanA* *E. faecium*, in Denmark is of concern, especially since VVE diagnostic is challenging. Because of this, the clone is likely to be underdiagnosed, which facilitates further spread. Since cross-border spread has been described for VRE, countries with patients transferred from Denmark should be aware of the vancomycin-variable ST1421-CT1134 *vanA* *E. faecium* clone.

Acknowledgements

We thank Karin Sixhøj Pedersen and Frank Hansen for their excellent technical assistance.

Conflict of interest

None declared.

Authors' contributions

Mette Pinholt, Louise Roer, Hülya Kaya, Peder Worning, Sanne Nygaard, Marianne Engell Clausen, Karen Leth Nielsen, Jurgita Samulionienė, Mona Kjærsgaard, Claus Østergaard, Ulrik S Justesen, John Coia, Turid Snekløth Søndergaard, Shahin Gaini, Kristian Schønning, Henrik Westh, Henrik Hasman and Barbara Holzknecht contributed to the revision of the manuscript and approved the final version. Louise Roer, Hülya Kaya, Anette M Hammerum and Henrik Hasman did the molecular analysis. Mette Pinholt, Peder Worning, Kristian Schønning and Henrik Westh shared WGS data for many of the VRE/VVE isolates from DCM

Hvidovre. Ulrik S Justesen, Mette Pinholt, Marianne Engell Clausen, Karen Leth Nielsen, Sanne Nygaard, Michael Kemp, Jurgita Samulionienė, Mona Kjærsgaard, Claus Østergaard, John Coia, Turid Snekloth Søndergaard, Kristian Schønning, Henrik Westh and Barbara Holzkecht detected VRE/VVE at the DCMs in Denmark. Shahin Gaini shared isolates and data on the VRE/VVE from the Faroe Islands.

Anette M Hammerum and Barbara Holzkecht drafted the manuscript. Anette M Hammerum incorporated comments, additions and feedback throughout the revision.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2019.

References

1. Sivertsen A, Pedersen T, Larssen KW, Bergh K, Rønning TG, Radtke A, et al. A Silenced vanA Gene Cluster on a Transferable Plasmid Caused an Outbreak of Vancomycin-Variable Enterococci. *Antimicrob Agents Chemother*. 2016;60(7):4119-27. <https://doi.org/10.1128/AAC.00286-16> PMID: 27139479
2. Kohler P, Eshaghi A, Kim HC, Plevneshi A, Green K, Willey BM, et al. Toronto Invasive Bacterial Diseases Network (TIBDN). Prevalence of vancomycin-variable Enterococcus faecium (VVE) among vanA-positive sterile site isolates and patient factors associated with VVE bacteremia. *PLoS One*. 2018;13(3):e0193926. <https://doi.org/10.1371/journal.pone.0193926> PMID: 29566004
3. Szakacs TA, Kalan L, McConnell MJ, Eshaghi A, Shahinas D, McGeer A, et al. Outbreak of vancomycin-susceptible Enterococcus faecium containing the wild-type vanA gene. *J Clin Microbiol*. 2014;52(5):1682-6. <https://doi.org/10.1128/JCM.03563-13> PMID: 24523464
4. Coburn B, Low DE, Patel SN, Poutanen SM, Shahinas D, Eshaghi A, et al. Vancomycin-variable Enterococcus faecium: in vivo emergence of vancomycin resistance in a vancomycin-susceptible isolate. *J Clin Microbiol*. 2014;52(5):1766-7. <https://doi.org/10.1128/JCM.03579-13> PMID: 24523476
5. Hansen TA, Pedersen MS, Nielsen LG, Ma CMG, Sørensen LM, Worning P, et al. Emergence of a vancomycin-variable Enterococcus faecium ST1421 strain containing a deletion in vanX. *J Antimicrob Chemother*. 2018;73(11):2936-40. <https://doi.org/10.1093/jac/dky308> PMID: 30113682
6. Hammerum AM, Baig S, Kamel Y, Roer L, Pinholt M, Gumpert H, et al. Emergence of vanA Enterococcus faecium in Denmark, 2005-15. *J Antimicrob Chemother*. 2017;72(8):2184-90. <https://doi.org/10.1093/jac/dkx138> PMID: 28541565
7. The Danish Integrated Antimicrobial Resistance Monitoring and Research Programme (DANMAP). DANMAP 2017 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Copenhagen: DANMAP; 2017. Available from: <https://www.danmap.org/-/media/arkiv/projekt-sites/danmap/danmap-reports/danmap-2017/danmap2017.pdf?la=en>.
8. de Been M, Pinholt M, Top J, Bletz S, Mellmann A, van Schaik W, et al. Core Genome Multilocus Sequence Typing Scheme for High-Resolution Typing of Enterococcus faecium. *J Clin Microbiol*. 2015;53(12):3788-97. <https://doi.org/10.1128/JCM.01946-15> PMID: 26400782
9. Pinholt M, Bayliss SC, Gumpert H, Worning P, Jensen VVS, Pedersen M, et al. WGS of 1058 Enterococcus faecium from Copenhagen, Denmark, reveals rapid clonal expansion of vancomycin-resistant clone ST80 combined with widespread dissemination of a vanA-containing plasmid and acquisition of a heterogeneous accessory genome. *J Antimicrob Chemother*. 2019;74(7):1776-85. <https://doi.org/10.1093/jac/dkz118> PMID: 30929020
10. van Hal SJ, Beukers AG, Timms VJ, Ellem JA, Taylor P, Maley MW, et al. Relentless spread and adaptation of non-typeable vanA vancomycin-resistant Enterococcus faecium: a genome-wide investigation. *J Antimicrob Chemother*. 2018;73(6):1487-91. <https://doi.org/10.1093/jac/dky074> PMID: 29566173

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.